Trials / Completed
CompletedNCT03224793
Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of BIIB059 in Healthy Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB059 | Administered as specified in the treatment arm |
| DRUG | Placebo | Administered as specified in the treatment arm |
Timeline
- Start date
- 2017-10-04
- Primary completion
- 2018-06-12
- Completion
- 2018-06-12
- First posted
- 2017-07-21
- Last updated
- 2018-08-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03224793. Inclusion in this directory is not an endorsement.